- Email: [email protected]
5433955 Site specific in vivo activation of therapeutic drugs
Healthcare Products
drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.
5433948 CLONING AND SEQUENCING OF ALLERGENS OF DERMATOPHAGOIDES (HOUSE DUST MITE) Thomas Wayne R; Chua Kaw-Yan Nedlands, AUSTRALIA The present invention features isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major D. farinae allergens, Der fI and Der f II and DNA encoding the major D. pteronyssinus allergens, Der p I and Der p II. The present invention further relates to proteins and peptides encoded by the isolated D. farinae and D. pteronyssinus DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use a diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.
5434046 DIAGNOSTIC ASSAY BASED ON CIS-PLAIN DRUG RESISTANCE GENE Enns Robert E; Howell Stephen B Solano Beach, CA, UNITED STATES assigned to The Regents of the University of Califoruia This invention relates to DNA encoding drug resistance to cis-platin. The invention also includes expression products of, and vectors and hosts comprising the DNA sequence encoding cis-platin resistance. Also included are immunodiagnostic assays of cis-platin resistance and assays for screening materials having a modulating effect on DNA encoding the cis-platin resistance gene and on the expression product thereof. The invention is further directed to antagonists to the cis-platin resistance gene and the expression product thereof. Recombinant and pharmaceutical means making use of the cis-platin resistance gene and its expression product are also provided.
5433955 SITE SPECIFIC IN VIVO ACTIVATION OF THERAPEUTIC DRUGS Bredehorst Reinhard; Kim Chong-Ho; McCabe Richard; Pomato Nicholas; Vogel Carl-Wilhelm Washington, DC, UNITED STATES assigned to Akzo N V
5434053 A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active
DETECTION
OF ANTIBIOTICS
Piasio Roger South Portland, ME, UNITED STATES assigned to Gist-Brocades N V 569
drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.
5433948 CLONING AND SEQUENCING OF ALLERGENS OF DERMATOPHAGOIDES (HOUSE DUST MITE) Thomas Wayne R; Chua Kaw-Yan Nedlands, AUSTRALIA The present invention features isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major D. farinae allergens, Der fI and Der f II and DNA encoding the major D. pteronyssinus allergens, Der p I and Der p II. The present invention further relates to proteins and peptides encoded by the isolated D. farinae and D. pteronyssinus DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use a diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.
5434046 DIAGNOSTIC ASSAY BASED ON CIS-PLAIN DRUG RESISTANCE GENE Enns Robert E; Howell Stephen B Solano Beach, CA, UNITED STATES assigned to The Regents of the University of Califoruia This invention relates to DNA encoding drug resistance to cis-platin. The invention also includes expression products of, and vectors and hosts comprising the DNA sequence encoding cis-platin resistance. Also included are immunodiagnostic assays of cis-platin resistance and assays for screening materials having a modulating effect on DNA encoding the cis-platin resistance gene and on the expression product thereof. The invention is further directed to antagonists to the cis-platin resistance gene and the expression product thereof. Recombinant and pharmaceutical means making use of the cis-platin resistance gene and its expression product are also provided.
5433955 SITE SPECIFIC IN VIVO ACTIVATION OF THERAPEUTIC DRUGS Bredehorst Reinhard; Kim Chong-Ho; McCabe Richard; Pomato Nicholas; Vogel Carl-Wilhelm Washington, DC, UNITED STATES assigned to Akzo N V
5434053 A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active
DETECTION
OF ANTIBIOTICS
Piasio Roger South Portland, ME, UNITED STATES assigned to Gist-Brocades N V 569